Rosemary Akhurst, PhD
Professor of Anatomy
Cancer Research Institute and UCSF Comprehensive Cancer Center
Graduate Program Membership: BMS, DSCB
Dr. Akhurst’s research is focused on mouse developmental and cancer genetics, and the translation of findings to study of human vascular diseases and cancer. Her group is characterizing genetic modifiers of TGFbeta signaling and how these genomic variants alter the outcome of disease processes. TGFbeta signaling is a central player in cancer, vascular, and stem cell biology, as well as cancer drug-resistance, thus these basic science questions provide critical insights into human disease mechanisms.
Allan Balmain, PhD, FRSE
Barbara Bass Bakar Endowed Chair in Cancer Genetics
Cancer Research Institute and Biochemistry and Biophysics
Graduate Program Membership: BMS, PSPG
Dr. Balmain’s laboratory uses crosses between highly genetically divergent strains of mice to explore the genetic basis of cancer susceptibility. His group has identified several of the somatic genetic events involved in initiation or progression of cancers induced by exposure to chemical mutagens or radiation. Recent emphasis is on computational approaches to the analysis of gene expression architecture in normal tissues and cancers from the same animals, as a route to unraveling the complex networks that underlie cancer susceptibility.
Sourav Bandyopadhyay, PhD
Assistant Professor of Bioengineering and Therapeutic Sciences
Graduate Program Membership: BMI, BMS, DSCB, PSPG
Website | UCSF Faculty Profile
The Bandyopadhyay lab uses systems biology approaches to understand how cellular pathways are organized and reshaped in diseases. We are developing new high throughput protein-protein and genetic interaction mapping platforms and computational approaches for integrating experimental data with larger pictures of pathways and networks. The major focus of the lab is on developing networks maps to dissect components of oncogene addiction and to identify new precision therapies in cancer.
Atul Butte, MD, PhD
Director of Institute for Computational Health Sciences
Professor of Pediatrics
Executive Director for Clinical Informatics, University of California Health Sciences and Services
Graduate Program Membership: BMI, iPQB, PSPG
Dr. Butte builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data — measured by researchers and clinicians over the past decade and now colloquially known as “big data” — into diagnostics, therapeutics, and new insights into disease. His lab has developed tools to analyze genomic data sets, and has used these tools to develop new uses for existing drugs, and new diagnostics. Dr. Butte was part of the team treating the first patient presenting with a whole genome. A major new focus is the analysis of clinical data from electronic health records.
James Cleaver, PhD
Professor Emeritus of Dermatology and of Pharmaceutical Chemistry
Graduate Program Membership: BMS
Dr. Cleaver focuses on human DNA repair deficient hereditary diseases, especially xeroderma pigmentosum (XP) and Cockayne Syndrome (CS), which present increased solar-induced cancers, and developmental and neurological disorders. He is carrying out whole exome sequencing of non-melanoma skin cancers that occur with extremely high frequency in an inbred XP community in Central America. He is also characterizing redox dysregulation of CS cells and identifying mitochondrial and extracellular sources of oxidative DNA damage in fibroblasts and neurons. His laboratory is developing induced pluripotent stem cells from XP and CS fibroblasts to investigate mechanisms of neurodegeneration that may lead to therapeutic intervention.
Aaron Diaz, PhD
Assistant Professor of Neurological Surgery
Graduate Program Membership: BMS
Dr. Diaz studies the role of neurodevelopmental programs in malignant gliomas, using computational and systems approaches. By contrasting genetic and epigenetic signatures between the developing human cortex and human brain tumors, Dr. Diaz is elucidating developmental pathways that are aberrantly activated during oncogenesis, promoting tumor growth and self-renewal. The Diaz lab is currently using high-throughput, single-cell assays, coupled with modern techniques from machine learning and data science, to identify therapeutic targets within these critical pathways.
Laura Fejerman, PhD
Associate Professor of Medicine
Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.
Franklin Huang, MD, PhD
Assistant Professor, Department of Medicine
Graduate Program Membership: PSPG
Dr. Huang studies biological processes relating to cancer disparities with a focus in prostate cancer. His lab uses cancer genomics including single-cell approaches to understand mechanisms that drive lethal, aggressive disease. The systems span from cell culture to in vivo model and his laboratory uses computational and experimental approaches to understand how cancer genes are regulated and how they function in cells. A major focus is to identify and uncover roles for cancer genes and identify new cancer vulnerabilities. Another focus of the lab is to understand the genomics of telomere maintenance in cancer cells.
Yun-Fai Chris Lau, PhD
Professor of Medicine
Research Career Scientist, VA Medical Center, San Francisco
Dr. Lau is interested in understanding the functions of the Y chromosome genes and their homologues in human development, physiology and disease. Recent efforts are focused on the gene regulatory hierarchy in mammalian sex determination and differentiation, the contrasting roles of a Y-located oncogene and its X-homologue tumor suppressor in human oncogenesis, and the contributions of the Y chromosome genes in sexual dimorphisms in human diseases, such as autism, Hirschsprung disease, and hepatocellular carcinoma with high male preference in the respective patient populations. Various advanced molecular genetic, genomic, proteomic, and transgenic mouse modeling strategies are utilized in these studies.
Alex Marson, MD, PhD
Associate Professor of Microbiology and Immunology, Scientific Director of Biomedicine, Innovative Genomics Institute (IGI)
Graduate Program Membership: BMS
Our lab decodes genetic circuits that control human immune cell function in health and disease. We have begun to identify autoimmunity risk variants that disrupt immune cell circuits. We have developed tools for CRISPR genome engineering in primary human T cells. We are testing how coding and non-coding genetic variation controls functional programs in the immune system. Genome engineered human T cells hold great potential for the next generation of cell-based therapies for cancer, autoimmunity, and infectious diseases.
Aleksandar Rajkovic, MD, PhD
UCSF Chief Genomics Officer
Professor, Department of Pathology, and Obstetrics, Gynecology and Reproductive Sciences
Our interests lie in the basic and translational research in reproductive genomics. We study reproductive tract pathologies in the context of developmental biology. We use both human studies and animal models to discover genes relevant to human pathologies. Our studies aim to reveal mechanisms of reproductive tract development, from embryo to adulthood, as well as to identify diagnostic and therapeutic targets for reproductive pathologies such as ovarian failure, uterine fibroids, and reproductive tract cancers.
A. Hunter Shain, PhD
Assistant Professor, Department of Dermatology
Dr. Shain utilizes a variety of –omic approaches to better understand the biology of melanoma. The laboratory has made important contributions discovering melanoma driver genes and delineating the evolution of melanoma. These areas remain an important focus of the laboratory. The laboratory is also heavily engaged in single-cell DNA/RNA sequencing, illuminating many aspects of cancer biology that are poorly understood due to limitations of current technologies geared towards bulk cell analyses.
Marina Sirota, PhD
Associate Professor, Institute for Computational Health Sciences
Dr. Sirota is interested in developing computational methods in integrative biology and applying these approaches in the context of disease diagnostic and therapeutics. She has extensive background in bioinformatics and data integration in the context of drug repositioning, drug target identification, clinical and molecular data analysis. Dr. Sirota has a long standing interest in studying genetic architecture in complex disease as well as novel applications of next-generation sequencing techniques with a special focus on autoimmune disease.
Jessica Van Ziffle, PhD
Assistant Professor, Department of Pathology
Dr. Van Ziffle directs clinical molecular genetic testing at the UCSF Clinical Cancer Genomics Lab (CCGL), and Genomic Medicine Lab (GML). Molecular testing techniques include single gene testing, as well as highly multiplexed deep sequencing technologies. The aim of this testing is to identify therapeutic targets, clarify a patient’s diagnosis, or establish a patient’s molecular diagnosis. Of particular interest are the genomics of hematopoietic malignancies, the heritable causes of these malignancies, and the clinical utility of exome sequencing for inherited diseases. Ongoing projects aim to improve the delivery of genomic information to patients through the electronic health record system.
John Wiencke, PhD
Professor of Neurological Surgery
Dr. Wiencke’s area of interest is in cytogenetics, radiation biology, and molecular epidemiology. His research has focused on biomarkers of exposure to chemical toxins and tobacco smoke and on genetic susceptibility to environmental exposures. He is the director of the laboratory providing support for epidemiological and clinical studies in neuroepidemiology. His laboratory is currently studying molecular subgroups of glioma and aberrant gene methylation, as well as genetic and environmental determinants of lung cancer.
John Witte, PhD
Professor of Epidemiology and Biostatistics and of Urology
Co-Leader, Program in Cancer Genetics, Helen Diller Cancer Center
Graduate Program Membership: ETS, iPQB, PSPG
Dr. Witte’s research constitutes applied and methodologic genetic epidemiology, with the aim of deciphering the mechanisms underlying complex diseases. His applied work is primarily focused on prostate cancer, while much of his methodologic work is on association studies and hierarchical modeling. Dr. Witte initiated a series of prostate cancer genetic epidemiology studies, which have had numerous successes toward sorting out the genetic basis of this disease. In particular, using a combination of genome-wide scan, allelic imbalance, and association studies, Dr. Witte and colleagues have isolated distinct chromosomal regions that appear to harbor genes that cause prostate cancer.
Margaret Wrensch, PhD
Professor and Lewis Chair in Brain Tumor Research, Department of Neurological Surgery
Dr. Wrensch investigates the genetic and molecular epidemiology of adult brain cancer as principal investigator of the ongoing population based case-control “Adult Glioma Study.”. She also co-leads a project within the UCSF Brain Tumor SPORE.. Her research group was among the first to establish risk loci for glioma and discovered a SNP that confers a six-fold increased risk for certain subtypes of glioma. She also has focused research efforts on the etiology of meningioma, and lung, breast and other cancers.
Elad Ziv, MD
Dr. Ziv’s research is focused on identifying genetic factors that underlie complex traits in humans. It combines principles from population genetics and epidemiology, particularly on diseases in populations of mixed ancestry such as African Americans and Latinos. His group is most interested in understanding susceptibility to cancer and response to cancer treatment. Current projects include identifying loci that influence breast cancer susceptibility among Latinas and identifying loci that influence mammographic breast density, a strong risk factor for breast cancer. They have also studied a variety of benign and malignant hematological conditions and study genetic factors that affect multiple myeloma.